



AMENDMENTS TO THE CLAIMS:

1. **(Currently Amended)** An ~~anti-tumor~~ **anti-leukemia** pharmaceutical composition comprising a N-vanillyl fatty acid amide of formula (1):



wherein -CO-R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

2. **(Original)** An anti-melanoma pharmaceutical composition comprising a N-vanillyl fatty acid amide of formula (1):



wherein -CO-R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

3. **(Original)** The pharmaceutical composition according to claims 1 or 2 wherein the -CO-R group is a member selected from the group consisting of saturated fatty acid residues containing from 14 to 32 carbon atoms.

4. **(Original)** The pharmaceutical composition according to claim 3 wherein the -CO-R group is a member selected from the group consisting of myristic acid residue (C14), palmitic acid residue (C16) and stearic acid residue (C18).

5. **(Original)** The pharmaceutical composition according to claims 1 or 2 wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues containing from 14 to 32 carbon atoms.

6. **(Original)** The pharmaceutical composition according to claim 5 wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues having from 1 to 3 double bonds and containing 18 carbon atoms and unsaturated fatty acid residues having 4 or 5 double bonds and containing 20 carbon atoms.


7. **(Original)** The pharmaceutical composition according to claim 6 wherein the -CO-R group is a member selected from the group consisting of oleic acid residue (C18:1), ricinoleic acid residue (C18:1), linoleic acid residue (C18:2), linolenic acid residue (C18:3) and eleostearic acid residue (C18:3).

8. **(Original)** The pharmaceutical composition according to claim 6 wherein the -CO-R group is a member selected from the group consisting of arachidonic acid residue (C20:4) and eicosapentaenoic acid residue (C20:5).

9. **(Original)** The pharmaceutical composition according to claim 5 wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues having four or more double bonds and containing 22, 24, 26, 28 or 32 carbon atoms.

10. **(Original)** The pharmaceutical composition according to claim 9, wherein the -CO-R group is 4,7,10,13,16,19-docosahexaenoic acid residue (C22:6).

11. **(Currently Amended)** A method for the treatment of ~~tumor~~ **melanoma or leukemia** comprising administering **to a patient in need thereof** a N-vanillyl fatty acid amide of formula (1):



wherein -CO-R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

12. -14. **(Canceled)**

15. **(New)** The method of claim 11, wherein the -CO-R group is a member selected from the group consisting of saturated fatty acid residues containing from 14 to 32 carbon atoms.

16. **(New)** The method of claim 15, wherein the -CO-R group is a member selected from the group consisting of myristic acid residue (C14), palmitic acid residue (C16) and stearic acid residue (C18).

17. **(New)** The method of claim 11, wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues containing from 14 to 32 carbon atoms.

18. **(New)** The method of claim 17, wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues having from 1 to 3 double bonds and containing 18 carbon atoms and unsaturated fatty acid residues having 4 or 5 double bonds and containing 20 carbon atoms.

19. **(New)** The method of claim 18, wherein the -CO-R group is a member selected from the group consisting of oleic acid residue (C18:1), ricinoleic acid residue (C18:1), linoleic acid residue (C18:2), linolenic acid residue (C18:3) and eleostearic acid residue (C18:3).

20. **(New)** The method of claim 18, wherein the -CO-R group is a member selected from the group consisting of arachidonic acid residue (C20:4) and eicosapentaenoic acid residue (C20:5).

21. **(New)** The method of claim 17, wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues having four or more double bonds and containing 22, 24, 26, 28 or 32 carbon atoms.

22. **(New)** The method of claim 21, wherein the -CO-R group is 4,7,10,13,16,19-docosahexaenoic acid residue (C22:6).